Skip to content

Nuvectis Pharma, Inc. NVCT Prepaid & Other Current

Prepaid & Other Current at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$1.7M+97.6%
Immunome logo
ImmunomeIMNM
$11.62M+100%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
$20.46M+53.5%
Exelixis logo
ExelixisEXEL
$75.88M+29.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$9.52M-31.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$20.44M+81.2%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s prepaid & other current?
Nuvectis Pharma, Inc. (NVCT) reported prepaid & other current of $268K in Q1 2026.
How has Nuvectis Pharma, Inc.'s prepaid & other current changed year-over-year?
Nuvectis Pharma, Inc.'s prepaid & other current decreased by 5.6% year-over-year, from $284K to $268K.
What is the long-term trend for Nuvectis Pharma, Inc.'s prepaid & other current?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s prepaid & other current has grown at a -4.7% compound annual growth rate (CAGR), from $91K to $75K.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.